0

Lilly partners with OpenAI to develop medicines for drug-resistant bacteria – ET HealthWorld | Pharma

LONDON: Eli Lilly said on Tuesday that it would cooperate OpenAI Leveraging your generative AI to evolve Antimicrobial which can be used to treat drug resistant bacteria,

why is it important?

Public health authorities, such as the World Health Organization, and industry experts have expressed concern over the limited availability of new treatments to combat the disease. antibiotic resistant bacteriaAbout which he says that this is not enough to deal with so-called terrorism Superbugs,

Antimicrobial resistance occurs when bacteria, viruses, fungi, and parasites change over time and no longer respond to antimicrobial resistance. MedicinesThis makes infections more difficult to treat and increases the risk of spreading the disease, becoming seriously ill, and dying.

More than 2.8 million antimicrobial-resistant infections occur each year in the United States.

Context

This partnership supports Lilly’s prior commitment, which began in 2020 when it pledged $100 million to the AMR Action Fund.

The fund was launched to help struggling antibiotic manufacturers combat the threat of antibiotic-resistant bacteria.

By the numbers

AMR Action is a $1 billion fund that aims to bring in 2 to 4 new entrants Antibiotic medicines This facility will be made available to the patients by 2030.

(Reporting by Christy Santosh in Bengaluru; Editing by Shounak Dasgupta)

  • Published on June 26, 2024 05:59 AM IST

Join a community of 2M+ industry professionals

Subscribe to our newsletter to get the latest information and analysis.

Download ETHealthworld App

  • Get realtime updates
  • Save your favourite articles

icon g play - 2

icon app store - 4


Scan to download the app
health barcode - 6

lilly-partners-with-openai-to-develop-medicines-for-drug-resistant-bacteria-et-healthworld-pharma